Women\'s health

Nextiles and Lilu Partner to Offer New Technology Solution for Mothers as Breastfeeding Awareness Month Kicks Off

Retrieved on: 
Tuesday, August 3, 2021
Breastfeeding, Anatomy, Branches of biology, Women\'s health, Lilu, Bra, Lactation, Breast

Nextiles works with partners across a range of industries to develop personalized, fabric-based sensors to power clothing for consumers everyday needs.

Key Points: 
  • Nextiles works with partners across a range of industries to develop personalized, fabric-based sensors to power clothing for consumers everyday needs.
  • The bra will collect data to provide mothers with insights about their lactation, to help them reach their breastfeeding goals.
  • We created Lilu to offer a line of smart bras designed specifically to help new moms adapt to breastfeeding more seamlessly, said Adriana Vazquez, Lilu CEO and Co-founder.
  • Nextiles, an NSF Innovation Corps (I-Corps) program participant, will serve as a subawardee and license its core technology to Lilu.

Female Infertility Treatment Drugs Market by Therapy, Route of Administration, Distribution Channel, and Region - Global Size, Share, Outlook, and Opportunity Analysis, 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021
Women, Consumer, Health, Parenting, Pharmaceutical, Fertility medicine, Organ systems, Medical specialties, Women\'s health, Women's health, Ferring Pharmaceuticals, Infertility, Female infertility, Polycystic ovary syndrome, Pharmaceutical industry in China, Evotec

The "Female Infertility Treatment Drugs Market, by Therapy, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Female Infertility Treatment Drugs Market, by Therapy, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Market players are focusing on various growth strategies such as agreements, partnerships, and collaborations to accelerate the development of drugs for infertility treatment, which is expected to boost growth of the global female infertility treatment drugs market over the forecast period.
  • For instance, in January 2020, Bayer AG announced the expansion of their partnership with Evotec SE, a biotechnology company focusing on women health, with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS), which is one of the causes of infertility in females.
  • Moreover, in January 2019, Ferring Pharmaceuticals, a biopharmaceutical company entered into an exclusive agreement with Sun Pharmaceutical Industries Ltd., an India-based multinational pharmaceutical company to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate injection which is used for treatment of female infertility.

Michael J. Hervey II, MD is recognized by Continental Who's Who

Retrieved on: 
Tuesday, July 6, 2021
Gynaecology, Obstetrics, Obstetrics and gynaecology, Medical specialties, Human reproduction, Women\'s health

PHOENIX, July 6, 2021 /PRNewswire/ -- Michael J. Hervey II, MD is being recognized by Continental Who's Who as a Top OBGYN for his professional excellence in the medical field and his unwavering commitment to serving the medical community through Premier Ob/Gyn LLC.

Key Points: 
  • PHOENIX, July 6, 2021 /PRNewswire/ -- Michael J. Hervey II, MD is being recognized by Continental Who's Who as a Top OBGYN for his professional excellence in the medical field and his unwavering commitment to serving the medical community through Premier Ob/Gyn LLC.
  • Dr. Michael J. Hervey II, a well-respected obstetrician and gynecologist, has led an impressive medical career, specializing in full-spectrum women's health.
  • Dr. Hervey has committed to supporting women's mental health and primary care throughout their pregnancy and beyond.
  • When he is not practicing medicine at Premier Ob/Gyn LLC, Dr. Hervey devotes his time to community work through Alpha Phi Alpha.

Women's Health Startup Natalist Expands to Nearly 6,000 Stores in National Retail Collaboration

Retrieved on: 
Wednesday, June 16, 2021
Reproduction, Articles, Fertility, Midwifery, Halle Tecco, Women's health, Women\'s health, Birth control, Obstetrics, Pregnancy, Rock Health, Natalism

NEW YORK, June 16, 2021 /PRNewswire/ -- Natalist , the mom-led women's health startup making doctor-approved fertility and pregnancy essentials with a net-zero plastic footprint, today announced an expansion to nearly 6,000 retail locations nationwide.

Key Points: 
  • NEW YORK, June 16, 2021 /PRNewswire/ -- Natalist , the mom-led women's health startup making doctor-approved fertility and pregnancy essentials with a net-zero plastic footprint, today announced an expansion to nearly 6,000 retail locations nationwide.
  • Products offered in retail include easy-to-use, beautiful, and convenient ovulation and pregnancy tests https://www.instagram.com/natalistco/ and a line of supplements formulated for conception and prenatal health.
  • And today I am thrilled to share that Natalist products are available in nearly 6,000 stores in every single state in the US.
  • Natalist is led by CEO Vernita Brown and Chief Women's Health Officer Halle Tecco, a prominent healthcare investor and founder and former CEO of digital health investment fund, Rock Health.

Women's Health App Market Size Worth $8.9 Billion By 2028 | CAGR: 19.0%: Grand View Research, Inc.

Retrieved on: 
Monday, June 14, 2021
Women's health, Women\'s health, Articles, Women, Midwifery, Maternal health, Menstrual cycle, Health software, Postpartum period, Health, Smartphone, Pregnancy

SAN FRANCISCO, June 14, 2021 /PRNewswire/ -- The global women's health app market size is expectedto reach USD 8.9 billion by 2028, based on a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, June 14, 2021 /PRNewswire/ -- The global women's health app market size is expectedto reach USD 8.9 billion by 2028, based on a new report by Grand View Research, Inc.
  • Increasing adoption of health apps, rising incidence of target disorders, and high smartphone penetration is expected to boost market growth during the forecast period.
  • There are various types of applications of health app in fitness and nutrition, menstrual health, pregnancy tracking and postpartum care, menopause, and disease management.
  • Grand View Research has segmented the global women's health app market on the basis of type and region:
    Women's Health App Type Outlook (Revenue, USD Million, 2016 - 2028)

Women's Health App Market Size Worth $8.9 Billion By 2028 | CAGR: 19.0%: Grand View Research, Inc.

Retrieved on: 
Monday, June 14, 2021
Women's health, Women\'s health, Articles, Women, Midwifery, Maternal health, Menstrual cycle, Health software, Postpartum period, Health, Smartphone, Pregnancy

SAN FRANCISCO, June 14, 2021 /PRNewswire/ -- The global women's health app market size is expectedto reach USD 8.9 billion by 2028, based on a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, June 14, 2021 /PRNewswire/ -- The global women's health app market size is expectedto reach USD 8.9 billion by 2028, based on a new report by Grand View Research, Inc.
  • Increasing adoption of health apps, rising incidence of target disorders, and high smartphone penetration is expected to boost market growth during the forecast period.
  • There are various types of applications of health app in fitness and nutrition, menstrual health, pregnancy tracking and postpartum care, menopause, and disease management.
  • Grand View Research has segmented the global women's health app market on the basis of type and region:
    Women's Health App Type Outlook (Revenue, USD Million, 2016 - 2028)

SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections

Retrieved on: 
Friday, April 30, 2021
Women's health, Human reproduction, Anatomy, Gynaecology, Human female reproductive system, Bacterial vaginosis, Vaginal discharge, Vagina, VVC, Women\'s health

b'The VANISH-306 study evaluated the safety and efficacy of oral ibrexafungerp as a treatment for patients with VVC (mITT 272 subjects).

Key Points: 
  • b'The VANISH-306 study evaluated the safety and efficacy of oral ibrexafungerp as a treatment for patients with VVC (mITT 272 subjects).
  • Severe VVC patients (VSS>7), categorized as complicated patients, accounted for 91.9%% of the patients in the in the study.
  • Typical VVC symptoms include pruritus, vaginal soreness, irritation, excoriation of vaginal mucosa and abnormal vaginal discharge.
  • The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.

InventHelp Inventor Develops Accessory to Simulate Breastfeeding (RHO-1225)

Retrieved on: 
Tuesday, April 6, 2021
Breastfeeding, Infant feeding, Brassieres, Women's clothing, Breast, Childhood, Bra, Human development, Women\'s health

PITTSBURGH, April 6, 2021 /PRNewswire/ -- "I wanted to create a way for all parents to enjoy the bonding experience of breastfeeding their baby," said an inventor, from Sandston, Va., "so I invented the BREASTFEEDING BRA.

Key Points: 
  • PITTSBURGH, April 6, 2021 /PRNewswire/ -- "I wanted to create a way for all parents to enjoy the bonding experience of breastfeeding their baby," said an inventor, from Sandston, Va., "so I invented the BREASTFEEDING BRA.
  • My design enables parents who are unable to breastfeed naturally to simulate the experience."
  • The patent-pending invention provides an effective way to simulate breastfeeding.
  • The original design was submitted to the Richmond sales office of InventHelp.

Certain Advertising Claims for FertilitySmart Conceive for Women Dietary Supplement Permanently Discontinued Following NAD Challenge

Retrieved on: 
Tuesday, March 23, 2021
Midwifery, Menstrual cycle, Human reproduction, Women\'s health, Ovulation, Theriogenology, Health sciences, Sexual reproduction, Fertility

The claims, which appeared in digital advertising, included:

Key Points: 
  • The claims, which appeared in digital advertising, included:
    "FertilitySmart Conceive for Women is recognized as a viable non-prescription option for women who are trying to get pregnant.
  • It encourages regular ovulation, supports regular menstrual cycles, and increases egg quality, without the risk of side effects associated with the drugs used in fertility treatment."
  • During the course of the proceeding, FertilitySmart informed NAD that instead of submitting substantiating evidence, it had permanently discontinued all of the challenged claims.
  • In reliance on the advertiser's representation, NAD did not review these claims on their merits.

Betoken Teams Up With Reality TV Star Chelsea Roy

Retrieved on: 
Wednesday, March 17, 2021
Organ systems, Women\'s health, Medical specialties, Adenomyosis, Polycystic ovary syndrome, Endometriosis, CBD, Chelsea, Massachusetts, Cannabis

The topical CBD cream also helps to soothe the chronic pain caused by diseases like Endometriosis, PCOS, adenomyosis, vaginosis, and more.

Key Points: 
  • The topical CBD cream also helps to soothe the chronic pain caused by diseases like Endometriosis, PCOS, adenomyosis, vaginosis, and more.
  • "Chelsea loves helping small and local businesses and at Betoken CBD we pride ourselves in bringing meaningful value to our customers.
  • The highly anticipated Betoken CBD cream giveaway in partnership with Chelsea Roy will be held from March 22 - 26, 2021.
  • Follow both Betoken CBD and Chelsea Roy on Instagram for the official rules, prizes, and how to enter.